Pregnancy, breastfeeding, and fertility
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medication.
Pregnancy:
The use of this medication is not recommended during pregnancy, unless your doctor considers it essential.
Breastfeeding:
It is not recommended to breastfeed while taking this medication.
Driving and operating machinery
This medication is unlikely to affect your ability to drive or operate machinery. However, some people may feel dizzy or tired occasionally when taking Propranolol. If this happens to you, seek advice from your doctor.
Propranolol Aurovitas contains lactose:
This medication contains lactose. If your doctor has told you that you have a certain sugar intolerance, consult with them before taking this medication.
Propranolol Aurovitas contains sodium:
This medication contains less than 23 mg of sodium (1 mmol) per tablet; this is essentially "sodium-free".
Use in athletes
This medication contains propranolol, which may produce a positive result in doping control tests.
Follow exactly the administration instructions of this medication as indicated by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again.
Swallow the propranolol tablet with water before meals. It must be swallowed whole. Do not chew.
Do not stop taking the medication unless your doctor tells you to.
Adults
The following table shows the recommended doses for an adult:
Recommended dose | Daily total dose (maximum) | |
Hypertension (high blood pressure) | Initially 40 mg two to three times a day, which can be increased to 80 mg per day at weekly intervals | 160 mg to 320 mg |
Angina (chest pain) and tremor | Initially 40 mg two to three times a day, which can be increased to 40 mg per day at weekly intervals | 120 mg to 240 mg |
Heart protection after a heart attack | Initially 40 mg four times a day and then change to 80 mg two times a day after a few days | 160 mg |
Migraine | Initially 40 mg two to three times a day, which can be increased to 40 mg per day at weekly intervals | 80 mg to 160 mg |
Arrhythmias(heart rhythm disorders), hyperthyroidism and thyrotoxicosis(certain thyroid conditions) and hypertrophic cardiomyopathy(thickened heart muscle) | 10 to 40 mg three or four times a day | 120 mg to 160 mg |
Phaeochromocytoma | Preoperative: 60 mg per day. | 30 mg to 60 mg |
Hypertensive liver disease | Initially 40 mg two times a day, increasing to 80 mg two times a day | 160 mg to 320 mg |
Pediatric population
Propranolol can also be used to treat children with migraine and arrhythmias:
- For migraine, the dose for children under 12 years is 20 mg two to three times a day, and for children 12 years or older, the adult dose is used.
- For arrhythmias, the dose will be adjusted by the doctor according to the child's age or weight.
Geriatric population
Older patients should start with the lowest dose. The optimal dose will be determined individually by the doctor.
Liver or renal insufficiency
The optimal dose will be determined individually by the doctor.
If you take more Propranolol Aurovitas than you should
In case of overdose or accidental ingestion, consult your doctor, pharmacist, or call the Toxicological Information Service, phone: 91 562 04 20, indicating the medication and the amount ingested. It is recommended to bring the packaging and the medication leaflet to the healthcare professional.
Overdose causes excessively slow heart rate, too low blood pressure, heart failure, and difficulty breathing with symptoms such as fatigue, hallucinations, fine tremors, confusion, nausea, vomiting, muscle spasms, fainting, or coma, low blood sugar level.Always bring the remaining tablets, packaging, and leaflet to identify the medication.
If you forgot to take Propranolol Aurovitas
If you forgot to take a dose, take it as soon as you remember. However, if it is almost time for the next dose, do not take the missed dose. Do not take a double dose to compensate for the missed dose.
If you interrupt treatment with Propranolol Aurovitas
Do not stop treatment without consulting your doctor first. In some cases, it may be necessary to interrupt treatment gradually.
If you have any other doubts about the use of this medication, ask your doctor or pharmacist.
Like all medicines, propranolol can cause side effects, although not everyone will experience them. The following side effects may occur with this medication:
Frequent: (may affect up to 1 in 10 patients):
Poorly frequent (may affect up to 1 in 100 patients):
Rare (may affect up to 1 in 1000 patients):
Very rare (may affect up to 1 in 10,000 patients):
Unknown (frequency cannot be estimated from available data):
Reporting of adverse effects
If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect that does not appear in this prospectus. You can also report them directly through the Spanish System for Pharmacovigilance of Medicines for Human Use:https://www.notificaram.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medication.
Keep this medication out of the sight and reach of children.
This medication does not require special storage conditions.
Do not use this medication after the expiration date that appears on the packaging after CAD. The expiration date is the last day of the month indicated.
Medications should not be disposed of through drains or in the trash. Dispose of the packaging and medications you no longer need at the SIGRE collection point at the pharmacy. Ask your pharmacist how to dispose of the packaging and medications you no longer need. By doing so, you will help protect the environment.
Composition of Propranolol Aurovitas
Core: Microcrystalline cellulose (Grade 101), Lactose monohydrate, Cornstarch, Sodium starch glycolate (Type A) from potato, Povidone (K-30), and Magnesium stearate.
Coating: Hypromellose 2910 (E464), Macrogol 6000 (E1521), Titanium dioxide (E171)
Appearance of the product and contents of the package
Coated tablet.
White to off-white, round, biconvex coated tablets, engraved on one face with “I” and on the other with “10”. The size is 5 mm.
Propranolol Aurovitas is available in PVC white opaque - aluminum blister packs
Package sizes:
Blister:20, 28, 30, 50, 56, 60, 90, 98, 100coated tablets.
Only some package sizes may be commercially available.
Marketing authorization holder and responsible manufacturer
Aurovitas Spain, S.A.U.
Avda. de Burgos, 16-D
28036 Madrid
Spain
Responsible manufacturer
APL Swift Services (Malta) Limited
HF26, Hal Far Industrial Estate, Hal Far
Birzebbugia, BBG 3000
Malta
or
Generis Farmaceutica, S.A.
Rua Joao de Deus, n° 19,
Venda Nova, Amadora
2700-487, Portugal
or
Arrow Génériques- Lyon
26 avenue Tony Garnier, Lyon,
69007, France
This medicine is authorized in the member states of the European Economic Area with the following names:
Germany | : Propranolol PUREN 10 mg Filmtabletten |
Netherlands | : Propranolol HCl Aurobindo 10 mg, filmomhulde tabletten |
Poland | : Propranolol Aurovitas |
Portugal | : Propranolol Generis |
Spain | : Propranolol Aurovitas 10 mg coated tablets EFG |
Last review date of this leaflet:March 2024
Further information on this medicine is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS) (http://www.aemps.gob.es)
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.